Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Deficit (Details Narrative)

Stockholders' Deficit (Details Narrative) - USD ($)						1 Months Ended	3 Months Ended		12 Months Ended
Stockholders' Deficit (Details Narrative) - USD ($)	Aug. 31, 2020	Jun. 30, 2020	Jun. 16, 2020	May 05, 2020	May 04, 2020	Sep. 30, 2017	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Common stock shares authorized							10,000,000,000		10,000,000,000
Common stock par value							$ 0.0001		$ 0.0001
Preferred stock shares authorized							5,000,000
Preferred stock par value							$ 0.01
Number of shares issued upon conversion, value									$ 1,001,000
Deemed dividend							$ 50,400,000
Debt converted into shares									38,371,250
Common stock shares issued							474,730,679		39,648,679
Common stock shares outstanding							474,730,679		39,648,679
Weighted average period							5 years 4 months 13 days
March 2017 Debentures [Member]
Number of warrants exercisable into common stock							12,300,000,000
Warrants exercise price							$ 0.0039
March 2017 Debentures [Member] \| Series A Warrants [Member]
Number of warrants exercisable into common stock							4,600,000,000
Warrants exercisable term							5 years
March 2017 Debentures [Member] \| Series B Warrants [Member]
Number of warrants exercisable into common stock							2,900,000,000
March 2017 Debentures [Member] \| Series C Warrants [Member]
Number of warrants exercisable into common stock							4,800,000,000
Warrants exercisable term							5 years
September 2017 Debentures [Member]
Number of warrants exercisable into common stock							6
Warrants exercise price							$ 9,016,133
Warrants [Member]
Number of warrants issued							13,800,000,000
Number of warrants issued as anti-dilution provision							9,300,000,000		4,500,000,000
2007 Equity Plan [Member]
Weighted average period							5 years 1 month 24 days
Intrinsic value of options exercisable							$ 0		$ 0
Exchange Agreement [Member]
Number of shares issued upon conversion, value					$ 250,000
Series H Preferred Stock [Member]
Preferred stock shares authorized							14,202		14,202
Preferred stock par value							$ 0.01		$ 0.01
Preferred stock shares outstanding							10		10
Preferred stock, stated value							$ 1,000
Series F Convertible Preferred Stock [Member]
Preferred stock shares outstanding									1,750,000
Series F Convertible Preferred Stock [Member] \| Genomas [Member]
Number of common shares issued						1,750,000
Number of common stock issued, value						$ 174,097
Series L Convertible Preferred Stock [Member]
Preferred stock shares outstanding									250,000
Series M Preferred Stock [Member]
Preferred stock shares authorized							30,000		30,000
Preferred stock par value							$ 0.01		$ 0.01
Preferred stock shares outstanding							22,000		22,000
Debt and accrued interest									$ 22,000,000
Debt description			Regardless of the number of shares of Series M Preferred Stock outstanding and so long as at least one share of Series M Preferred Stock is outstanding, the outstanding shares of Series M Preferred Stock shall have the number of votes, in the aggregate, equal to 51% of all votes entitled to be voted at any meeting of stockholders or action by written consent. Each outstanding share of the Series M Preferred Stock shall represent its proportionate share of the 51% allocated to the outstanding shares of Series M Preferred Stock in the aggregate.
Conversion rate			90.00%
Dividend rate			10.00%
Series M Preferred Stock [Member] \| Mr. Diamantis [Member]
Preferred stock shares authorized		30,000
Preferred stock par value		$ 1,000
Preferred stock, stated value		$ 0.01
Gain on extinguishment of debt		$ 18,800,000
Exchange of shares		22,000
Deemed dividend									3,200,000
Debt and accrued interest									$ 18,800,000
Series N Preferred Stock [Member]
Preferred stock shares authorized	50,000						50,000		50,000
Preferred stock par value	$ 1,000						$ 0.01		$ 0.01
Preferred stock shares outstanding							25,257		29,434
Preferred stock, stated value							$ 4,177,516
Dividend rate	10.00%
Debt conversion description	The conversion price is equal to 90% of the lowest VWAP during the 10 trading days immediately prior to the conversion date. Holders of the Series N Preferred Stock are prohibited from converting Series N Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% (or, upon election of the holder, 9.99%) of the total number of shares of common stock then issued and outstanding. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days after notice to the Company.
Debt converted into shares							4,177.516		1,001
Number of shares converted							435,082,000
Series H Preferred Stock [Member]
Weighted average common stock price percentage									85.00%
Series L Preferred Stock [Member]
Preferred stock shares authorized							250,000		250,000
Preferred stock par value							$ 0.01		$ 0.01
Preferred stock shares outstanding							250,000		250,000
Series L Preferred Stock [Member] \| Exchange Agreement [Member] \| Alcimede LLC [Member]
Number of shares issued upon conversion, value				$ 250,000
Series K Preferred Stock [Member] \| Exchange Agreement [Member] \| Alcimede LLC [Member]
Number of shares issued upon conversion, value				$ 250,000
Series I-1 and Series I-2 Preferred Stock [Member]
Debt converted into shares								25,000
Number of shares converted								21.25
Series I-1 and Series I-2 Preferred Stock [Member] \| Exchange and Redemption Agreement [Member]
Preferred stock shares authorized	30,435.52